Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK
-
Published:2023-05-16
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Wei Jia, Matthews Philippa C.ORCID, Stoesser NicoleORCID, Newton John N., Diamond Ian, Studley Ruth, Taylor Nick, Bell John I., Farrar Jeremy, Kolenchery Jaison, Marsden Brian D.ORCID, Hoosdally Sarah, Jones E. Yvonne, Stuart David I., Crook Derrick W., Peto Tim E. A., Walker A. Sarah, Pouwels Koen B.ORCID, Eyre David W.ORCID, Thomas Tina, Ayoubkhani Daniel, Black Russell, Felton Antonio, Crees Megan, Jones Joel, Lloyd Lina, Sutherland Esther, Pritchard Emma, Vihta Karina-Doris, Doherty George, Kavanagh James, Chau Kevin K., Hatch Stephanie B., Ebner Daniel, Ferreira Lucas Martins, Christott Thomas, Dejnirattisai Wanwisa, Mongkolsapaya Juthathip, Cameron Sarah, Tamblin-Hopper Phoebe, Wolna Magda, Brown Rachael, Cornall Richard, Screaton Gavin, Lythgoe Katrina, Bonsall David, Golubchik Tanya, Fryer Helen, Cox Stuart, Paddon Kevin, James Tim, House Thomas, Robotham Julie, Birrell Paul, Jordan Helena, Sheppard Tim, Athey Graham, Moody Dan, Curry Leigh, Brereton Pamela, Jarvis Ian, Godsmark Anna, Morris George, Mallick Bobby, Eeles Phil, Hay Jodie, VanSteenhouse Harper, Lee Jessica, White Sean, Evans Tim, Bloemberg Lisa, Allison Katie, Pandya Anouska, Davis Sophie, Conway David I., MacLeod Margaret, Cunningham Chris,
Abstract
AbstractFollowing primary SARS-CoV-2 vaccination, whether boosters or breakthrough infections provide greater protection against SARS-CoV-2 infection is incompletely understood. Here we investigated SARS-CoV-2 antibody correlates of protection against new Omicron BA.4/5 (re-)infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults ≥18 y from the United Kingdom general population. Higher antibody levels were associated with increased protection against Omicron BA.4/5 infection and breakthrough infections were associated with higher levels of protection at any given antibody level than boosters. Breakthrough infections generated similar antibody levels to boosters, and the subsequent antibody declines were slightly slower than after boosters. Together our findings show breakthrough infection provides longer-lasting protection against further infections than booster vaccinations. Our findings, considered alongside the risks of severe infection and long-term consequences of infection, have important implications for vaccine policy.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference57 articles.
1. Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626–636 (2021). 2. Bernal, J. L. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021). 3. Cerqueira-Silva, T. et al. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infect. Dis. 22, 791–801 (2022). 4. Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063–1071 (2022). 5. Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|